Price History

Hover for the daily close. The dotted line marks the period open.

Compare AGMB with… →

AGMB Key Statistics

As of Sep 4, 2026

Trading

Open: $14.83
Previous Close: $14.83
Day's Range: 14.53–15.86
52-Week Range: 8.75–17.82
Volume: 245.30K

Valuation

Market Cap: $777.13M
P/E Ratio: unprofitable
EPS (ttm): −1.57

Financials (FY)

Revenue (FY): $0.00
Net Income (FY): −$62.55M
Profit margin: 0.00%
Shares Outstanding: 49.25M

Dividend and dates

Avg Volume: 120.95K

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

AGMB Revenue and Earnings by Fiscal Year

FY ends December

RevenueNet income

2022202320242025

Fiscal year	Revenue	Net income	Net margin
2025	$0.00	−$62.55M	—
2024	$0.00	−$46.27M	—
2023	$0.00	−$11.39M	—
2022	$0.00	−$8.14M	—

Fiscal year	Revenue	Gross profit	Operating income	Net income	Net margin
2025	$0.00	—	−$59.28M	−$62.55M	—
2024	$0.00	—	−$48.02M	−$46.27M	—
2023	$0.00	—	−$31.19M	−$11.39M	—
2022	$0.00	—	−$22.63M	−$8.14M	—

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

AGMB Valuation vs Biotechnology Median

Median of 656 stocks

Metric	AGMB	Biotechnology median	vs median
Profit margin	0.00%	0.00%	0.0 pts above

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values AgomAb Therapeutics NV (AGMB) at $777.13M. The company sits in the Healthcare sector, in the Biotechnology industry. The company reports 62 employees.

AGMB last closed at $15.78 on September 4, 2026. That is +$0.95 (+6.41%) against the previous close. Over the past 52 weeks the price has ranged from $8.75 to $17.82. The latest close sits 80.34% above that 52-week low.

Financial Health

The most recent full year on file, fiscal 2025, shows revenue of $0.00. The same year closed with a net loss of $62.55M. The reported profit margin is 0%. Trailing earnings per share are −1.57.

Across the 4 fiscal years on file, revenue moves from $0.00 in 2022 to $0.00 in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published.

The stored price history starts on February 6, 2026, and the total return since then is +7.71%.

Growth & Income

No dividend is on file for AGMB.

2026 is still running; the price is +7.71% year to date.

Peer Comparison

AgomAb Therapeutics NV (AGMB) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company	Ticker	Market Cap	P/E Ratio
AgomAb Therapeutics NV	AGMB	$777.13M	—
Vertex Pharmaceuticals Incorporated	VRTX	$138.42B	32.5
Regeneron Pharmaceuticals, Inc.	REGN	$85.22B	20.5
argenx SE	ARGX	$64.25B	40.1

The Biotechnology industry average P/E ratio is 12.6x. AgomAb Therapeutics NV has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

ARGX

argenx SE

$64.25B

MRNA

Moderna, Inc.

$58.11B

RVMD

Revolution Medicines, Inc.

$45.01B

ONC

BeOne Medicines AG

$40.53B

View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

JNJ

Johnson & Johnson

$663.28B

ABBV

AbbVie Inc.

$453.19B

MRK

Merck & Co., Inc.

$370.89B

UNH

UnitedHealth Group Incorporated

$356.47B

View all Healthcare stocks →

About AgomAb Therapeutics NV

AgomAb Therapeutics NV, a clinical-stage biopharmaceutical company, develops novel disease-modifying therapies for immunology and inflammatory diseases in the United States. The company's product pipeline includes Ontunisertib (AGMB-129), an oral gastrointestinal-restricted small molecule inhibitor of ALK5 or TGFßR1 for the treatment of Fibrostenosing Crohn's disease, which is in Phase 2a clinical trials; and AGMB-447, an inhaled small molecule inhibitor of ALK5 or TGFßR1 for the treatment of idiopathic pulmonary fibrosis that is in Phase 1 clinical trials. It also develops AGMB-101, a HGF-mimetic monoclonal antibody that acts through agonism or stimulation of the MET receptor and has demonstrated antifibrotic and regenerative activity in preclinical models. The company was incorporated in 2017 and is headquartered in Antwerp, Belgium.

Visit website →

AgomAb Therapeutics NV (AGMB) Stock Analysis